Asif Khan, MD
Vascular Neurology · Bellevue, WANPI 1386805059
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,449 of the $8,620 with a category attached, or 63.2%. 28 manufacturers reported payments, led by Penumbra, Inc. at 29.1% of the total. Reporting peaked in 2019 at $2,997 and has fallen 61.3% since, to $1,160 in 2025.
Across 227 payments — averaging $37.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$3K
- Microvention, Inc.$2K
- Medtronic$1K
- Balt USA, LLC$739
- Imperative Care, Inc$492
- UCB, Inc.$180
- plus $1K from 22 others
Across 3 payments — averaging $1152.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Stryker$3K
What the payments were for
- Travel & lodging$3,17137%
- Food & beverage$5,44963%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 97 | $2,513 |
| Microvention, Inc. | 46 | $2,212 |
| Medtronic(2 entities) | 18 | $1,465 |
| Balt USA, LLC | 6 | $739 |
| Imperative Care, Inc | 16 | $492 |
| UCB, Inc. | 5 | $180 |
| AbbVie | 4 | $120 |
| Eisai Inc. | 4 | $110 |
| Teva Pharmaceuticals USA, Inc. | 3 | $94 |
| Stryker | 2 | $73 |
| Siemens Medical Solutions USA, Inc. | 2 | $61 |
| Abbott | 3 | $56 |
| Acadia Pharmaceuticals Inc | 2 | $55 |
| Lundbeck LLC | 2 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $51 |
| Upsher-smith Laboratories LLC | 2 | $51 |
| Boston Scientific | 2 | $45 |
| BK Medical Holding Company Inc. | 1 | $35 |
| SK Life Science, Inc. | 1 | $29 |
| Pfizer | 1 | $26 |
| Lilly USA, LLC | 1 | $26 |
| Novartis | 1 | $24 |
| Impel Pharmaceuticals Inc. | 1 | $24 |
| Tanabe Pharma America, Inc. | 1 | $24 |
| Integra Lifesciences Corporation | 1 | $20 |
| AstraZeneca | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few vascular neurology providers in Washingtonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 15 | $468 |
| Gabapentin | 11 | $115 |
| ClopidogrelClopidogrel Bisulfate | 22 | $52 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in Bellevue
- Ali Sultan-QurraieRenton$34K
- Sea Mi ParkOlympia$4K
- Rachael SchutzKirkland$1K
- Michael PrevitiRenton$549
- Kunakorn AtchaneeyasakulSeattle$505
- Sarabjit AtwalRichland$143
- Rizwan KalaniSeattle$123
- Jennifer ParySpokane$77
- Jonathan WeinsteinSeattle$14
- Breana TaylorSeattle$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.